Sponsor:
PharmaIN
Code:
NCT05490888
Conditions
Cirrhosis, Liver
Liver Fibrosis
Ascites Hepatic
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
PHIN-214 Subcutaneous injection
Brief summary:
Conditions
Cirrhosis, Liver
Liver Fibrosis
Ascites Hepatic
Study ID
NCT05490888
Start date
Jan 3, 2022
Status verified date
Sep, 2025
Completion date
Jun 30, 2026
Anticipated
Primary completion date
May 31, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
74 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: single dose of PHIN-214
experimental: multiple daily dosing of PHIN-214
Interventions
PHIN-214 Subcutaneous injection
Primary outcome measure
Central contacts
Locations
Arizona Liver Health
Recruiting
Chandler, Arizona, United States, 85224
Contacts
Southern California Research Center
Recruiting
Coronado, California, United States, 92118
Contacts
Tandem Clinical Research
Recruiting
Marrero, Louisiana, United States, 70072
Contacts
Mayo Clinic
Recruiting
Rochester, Minnesota, United States, 55905
Contacts
Cleveland Clinic
Recruiting
Cleveland, Ohio, United States, 44195
Contacts
University of Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contacts
Methodist Health System, Dallas Medical Center
Recruiting
Dallas, Texas, United States, 75203
Contacts
VA North Texas Healthcare System
Recruiting
Dallas, Texas, United States, 75216
Contacts
Principal Investigator:
Jacqueline O'Leary, MD
Texas Liver Institute
Recruiting
San Antonio, Texas, United States, 78215
Contacts
Sponsor
PharmaIN
Last update posted
Sep 5, 2025
Last verified
Sep, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by PharmaIN on 2025-09-05.